Compare Herbalife Nutrition Ltd (HLF) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Zoetis Inc — how do they compare? Herbalife Nutrition Ltd trades at $12.18 (market cap $1.25B), while Zoetis Inc trades at $74.04 (market cap $31.59B). The key difference: Zoetis Inc is far larger — about 25.3× Herbalife Nutrition Ltd's market cap, and Zoetis Inc pays a 2.81% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals.
| HLF | ZTS | |
|---|---|---|
Market Cap | $1.25B | $31.59B |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $156.76 |
52-Week Low | $7.75 | $71.91 |
Enterprise Value | $2.98B | $38.89B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLF trades at $12.04, up 0.42% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.64, beating expectations of $0.607, and raised full-year guidance. Revenue for 2025 was $5.04 billion with a net income margin of 4.66%, while valuation ratios remain low with a P/E of 5.38 and P/S of 0.25. Recent news includes Herbalife's inclusion in TIME's America's Best Companies 2026 and a $1.45 billion debt refinancing completed in April 2026.
The outlook for HLF is cautiously optimistic due to strong earnings beats and strategic initiatives, but risks include high debt levels and competitive pressures. Analyst consensus is 57.69% buy, with institutional sentiment leaning positive amid ongoing business transformation efforts.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
